Lung Transplantation – Pipeline Review, H1 2012
Global Markets Direct
January 23, 2012 46 Pages - SKU: GMD6776057
|
|
Lung Transplantation - Pipeline Review, H1 2012
Summary
Global Markets Direct’s, 'Lung Transplantation - Pipeline Review, H1 2012', provides an overview of the Lung Transplantation therapeutic pipeline. This report provides information on the therapeutic development for Lung Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lung Transplantation. 'Lung Transplantation - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope- A snapshot of the global therapeutic scenario for Lung Transplantation.
- A review of the Lung Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Lung Transplantation pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for Lung Transplantation.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Lung Transplantation pipeline depth and focus of Lung Transplantation therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
|
- Introduction
- Global Markets Direct Report Coverage
- Lung Transplantation Overview
- Therapeutics Development
- An Overview of Pipeline Products for Lung Transplantation
- Lung Transplantation Therapeutics under Development by Companies
- Lung Transplantation Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Lung Transplantation Therapeutics - Products under Development by Companies
- Lung Transplantation Therapeutics - Products under Investigation by Universities/Institutes
- Companies Involved in Lung Transplantation Therapeutics Development
- Quark Pharmaceuticals, Inc.
- Vectura Group plc
- Novartis AG
- PARI Pharma GmbH
- APT Pharmaceuticals, Inc.
- Fresenius Biotech GmbH
- Lung Transplantation - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- Afinitor - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Pulminiq - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Respiratory And Inflammatory Diseases Program - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- ATG-Fresenius S - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Certican - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- L-CsA - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- VR909 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Lung Transplantation Therapeutics - Drug Profile Updates
- Lung Transplantation Therapeutics - Dormant Products
- Lung Transplantation - Product Development Milestones
- Featured News & Press Releases
- Dec 06, 2011: Proteo And Its Subsidiary Announce Major Advances In Elafin Development Program
- Feb 24, 2010: APT Pharmaceuticals Completed Enrollment in Phase III for Inhaled Cyclosporine
- Feb 11, 2010: PARI Pharma Enrolls First Patient In Phase IIb Study Of L-CsA
- Sep 08, 2009: APEPTICO Presents Lead Product AP301 At Annual Congress Of European Respiratory Society In Vienna, Austria
- Jun 02, 2009: PARI Pharma Reports Successful Phase Ib Clinical Results For Inhaled Liposomal Cyclosporine A And Gains FDA Orphan Drug Designation For The Prevention And Treatment Of Bronchiolitis Obliterans
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for Lung Transplantation, H1 2012
- Products under Development for Lung Transplantation - Comparative Analysis, H1 2012
- Number of Products under Development by Companies, H1 2012
- Number of Products under Investigation by Universities/Institutes, H1 2012
- Comparative Analysis by Late Stage Development, H1 2012
- Comparative Analysis by Mid Clinical Stage Development, H1 2012
- Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
- Products under Development by Companies, H1 2012
- Products under Investigation by Universities/Institutes, H1 2012
- Quark Pharmaceuticals, Inc., H1 2012
- Vectura Group plc, H1 2012
- Novartis AG, H1 2012
- PARI Pharma GmbH, H1 2012
- APT Pharmaceuticals, Inc., H1 2012
- Fresenius Biotech GmbH, H1 2012
- Assessment by Monotherapy Products, H1 2012
- Assessment by Stage and Route of Administration, H1 2012
- Assessment by Molecule Type, H1 2012
- Lung Transplantation Therapeutics - Drug Profile Updates
- Lung Transplantation Therapeutics - Dormant Products
- List of Figures
- Number of Products under Development for Lung Transplantation, H1 2012
- Products under Development for Lung Transplantation - Comparative Analysis, H1 2012
- Products under Development by Companies, H1 2012
- Products under Investigation by Universities/Institutes, H1 2012
- Late Stage Products, H1 2012
- Mid Clinical Stage Products, H1 2012
- Discovery and Pre-Clinical Stage Products, H1 2012
- Assessment by Monotherapy Products, H1 2012
- Assessment by Route of Administration, H1 2012
- Assessment by Stage and Route of Administration, H1 2012
- Assessment by Molecule Type, H1 2012
- Assessment by Stage and Molecule Type, H1 2012
Share this report
Other tasks Related Markets Drug Discovery Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
